For emerging biotechs, speed is rarely a luxury. It is survival.
A Phase 1 start date may be tied to investor milestones. A rare disease therapy may represent a small patient population waiting on limited drug supply. A single batch may determine whether a clinical timeline stays on track. In each case, sponsors often assume that securing time on a high-speed automated isolator filling line is the fastest path forward.
In reality, that assumption frequently leads to longer timelines. While automated lines are indispensable for large-scale commercial manufacturing, manual aseptic filling in isolators often enables significantly faster start dates for early-phase and small-batch programs. The reason is simple: speed to clinic is driven more by flexibility and complexity than by units-per-minute output. Understanding that distinction can materially impact your development timeline.
The Assumption: Automation Equals Speed to Market
Automated filling lines are engineered for efficiency. They are designed to fill thousands—or tens of thousands—of units per hour with repeatable precision. For commercial products, large volume batches and late-stage programs, this efficiency is invaluable. However, output speed is not the same as onboarding speed.
Automated lines are optimized for scale, repeatability, and long production campaigns. They are not inherently optimized for rapid project initiation, frequent changeovers, or small-batch agility.
For sponsors developing early-phase material, the question is not, “How fast can the line fill?” It is, “How quickly can we get on the schedule and start?” These are two very different conversations with a CDMO.
What Often Delays Start Dates on Automated Lines
Automated lines introduce layers of complexity that can extend the time required to begin production—especially for small or novel programs.
Engineering Runs and Technical Complexity
High-speed lines require engineering studies to dial in:
- Fill accuracy
- Stoppering performance
- Crimp parameters
Automation programming may need adjustment to accommodate unique fill volumes, viscosities, or container formats. The more complex the system, the more variables must be tested and confirmed before GMP production begins. Filling studies to confirm the functional efficiency of the robotic fillers must be conducted prior to the GMP fill and can take weeks. A CDMO is also likely to recommend a machineability run for change parts and robotics on the automated line to ensure the fill volume is as intended. For early-phase sponsors working with limited API, these additional runs can also introduce material risk. Finally, the change parts themselves can be prohibitively expensive or have long lead times.
Manual lines do not have change parts, so no confidence-building studies are required beyond confirming that the pump is able to fill the required volume—which is more expedited and does not require a full study.
Scheduling Prioritization
In many facilities, automated lines are prioritized for:
- Phase III programs
- Commercial launches
- High-volume campaigns
Smaller early-phase batches may not receive the same scheduling urgency, simply because they are not the optimal economic fit for that equipment. The result? Longer lead times—even if the fill itself would only take a few hours.
Why Manual Aseptic Filling Enables Faster Start Dates
Manual aseptic filling environments are designed differently. They prioritize flexibility, adaptability, and precision for small batches. That structural difference often translates into shorter time-to-start.
1. Minimal Format Change Requirements
Manual filling suites require far fewer custom components. Because trained operators handle key steps within a controlled aseptic environment, container format adjustments are simpler.
This reduces:
- Engineering evaluations
- Part fabrication timelines
- Mechanical compatibility concerns
For sponsors using standard vials, syringes, or small specialty formats, onboarding can be significantly faster.
2. Simplified Setup and Turnover
Manual suites typically have:
- Smaller equipment footprints
- Reduced mechanical complexity
- Streamlined cleaning and preparation processes
In contrast to manual lines, set-up times for large, automated lines are typically long and carry high costs. Changeovers between products on manual lines are less burdensome than those required on high-speed automated lines. This allows CDMOs to turn suites around more quickly and allocate production slots with greater agility.
3. Streamlined Technical Transfer
Early-phase material often originates from lab-scale processes. Manual filling environments are inherently better suited to accommodating:
- Small batch volumes
- Limited API supply
- Non-standard fill volumes
Because the process is less mechanically constrained, adaptations can be made efficiently without extensive reconfiguration or programming. This flexibility reduces the time required for technical transfer and increases the likelihood of a smooth first GMP run.
For temperature or shear-sensitive products, manual lines allow a greater degree of flexibility to introduce process controls to protect the formulation, because unlike automated lines, process controls are not contained within the isolator.
4. Greater Scheduling Flexibility
Facilities that specialize in manual aseptic filling typically dedicate capacity specifically to small-batch and early-phase programs. Their business model is built around serving sponsors who need agility—not scale.
As a result, they can often offer:
- Faster slot allocation
- Shorter lead times
- Greater responsiveness to timeline shifts
For emerging biotechs working against funding milestones or regulatory windows, that scheduling flexibility can be the difference between staying on track and losing momentum.
5. Reduced API Risk During Startup
When working with high-value or scarce APIs, minimizing material loss is critical.
Manual filling:
- Allows filling with lower minimum volumes
- Can be optimized to reduce product waste
- Limits mechanical reject loss
For orphan and rare disease programs—where a single liter of drug product may represent enormous value—this reduced risk profile adds another layer of timeline protection.
Because automated systems are often designed for large batches, the amount of product loss that is considered “acceptable” during a fill is measured on a different scale than manual lines. Automated lines have longer sections of tubing to scale for larger batches, resulting in greater line loss than on a smaller-scale line. Weight checks, another source of product loss, can be modified for frequency on manual lines as desired. Automated line weight check intervals will be harder to modify and therefore result in larger product loss depending on the type of weight check. For the average large-scale product, the frequency of weight checks has less of an impact. For small batches, it is important to have more control over weight checks—a benefit offered by manual lines.
Ideal Use Cases for Manual Filling
Manual aseptic filling is not a compromise. It is a strategic choice for programs that prioritize timeline speed and flexibility over throughput.
It is particularly well suited for:
- Phase 1 and early Phase 2 clinical supply
- Orphan and rare disease therapies
- Personalized medicines or low-volume treatments
- High-cost biologics with limited API availability
For these programs, agility often outweighs automation. Manual filling lines are particularly well suited for clinical supply because they can readily accommodate dose adjustments throughout the course of a clinical trial. Unlike automated systems, which often require new change parts and revalidation before a dose change can be implemented, manual lines provide the flexibility to adapt more efficiently as clinical requirements evolve. Manual lines also allow for less line loss with limited or high value API, making them suitable for commercial filling of very expensive drug products.
Is Manual Filling “Less Advanced”?
A common misconception is that manual aseptic filling represents a lower standard of manufacturing. That is not the case.
Manual filling occurs within fully qualified GMP environments, supported by:
- ISO-classified cleanrooms
- Robust environmental monitoring
- Media fills and aseptic process simulations
- Highly trained, experienced operators
- Comprehensive SOPs and quality systems
- Digital validation systems and controls
Sterility assurance, compliance, and documentation rigor remain uncompromised. The difference is not quality. It is configuration. Manual filling is purpose-built for precision, control, and adaptability—making it an ideal solution for early-phase development.
Planning for Future Scale
Many programs that begin with manual filling will eventually scale to automated lines as demand increases.
A strategic CDMO partner can help you:
- Design early-phase batches with future transfer in mind
- Document process parameters to facilitate scale-up
- Identify the appropriate inflection point for automation
Starting with manual filling does not limit your long-term growth. In many cases, it accelerates it by allowing you to reach clinical proof-of-concept faster.
Speed Is About Fit, Not Just Equipment
Automated filling lines maximize throughput. Manual aseptic filling maximizes agility. For large commercial campaigns, automation is essential. But for early-phase, small-batch, and high-value programs, agility often determines how quickly you reach the clinic. Choosing the right fill-finish strategy is not about selecting the most advanced equipment. It is about selecting the approach that aligns with your stage, batch size, and timeline objectives.
For sponsors focused on rapid development and efficient use of precious API, manual aseptic filling frequently provides the faster—and smarter—path forward. The right CDMO will not simply offer capacity. They will help you choose the strategy that protects your material, your timeline, and your momentum.
About the author
Pranav Pandya is the Process Engineering Manager for the MSAT team at Sharp Sterile, with seven years of experience in pharmaceutical manufacturing. He has been with the company since 2018, where he has been closely involved in low-loss design processes and has developed strong expertise as a subject matter expert in low-volume sterile fills.
His work has focused on optimizing processes in GMP environments, improving efficiency, and ensuring reliable outcomes when working with limited quantities of drug substance.
